What does Energenesis Biomedical CO.,LTD. do?

Energenesis Biomedical CO.,LTD. (6657.TW) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6657.TW's market cap?

Energenesis Biomedical CO.,LTD. (6657.TW) has a market capitalization of approximately $2.69 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6657.TW pay a dividend?

No — Energenesis Biomedical CO.,LTD. (6657.TW) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6657.TW profitable?

Energenesis Biomedical CO.,LTD. (6657.TW) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6657.TW

Energenesis Biomedical CO.,LTD.

TAI·Biotechnology · Healthcare

NT$30.55NT$0.95+3.21%

Market capNT$2.69B·Market closed·Aug 26 5:30 AM UTC

Price Chart

NT$30.55+NT$0.95 (+3.21%)today

−54.27%CAGR −21.47%

Select date range

FromTo

Jun 1, 2023Jun 1, 2023 → Aug 26, 2026· 3.2 yrsAug 26, 2026

Key Metrics

6657.TW does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 17

Last Report DateAug 7

Reported vs Estimate−NT$0.56 vs −NT$0.56

Earnings Surprise+0.0%

FinancialsFinancials Tab

RevenueNT$7.64M

Net Income−NT$298.61M

Net Margin−3,908.5%

Operating Cash Flow−NT$230.55M

Capital ExpendituresNT$3.09M

Free Cash Flow−NT$233.64M

Return on Equity−41.9%

Return on Invested Capital−19.5%

Net CashNT$665.64M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6657.TW and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6657.TW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6657.TW and 80,000+ other tickers.

About Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses…

CEO: Han-min Chen
Sector: Healthcare
Industry: Biotechnology
Exchange: TAI
Employees: 35
Website: www.energenesis-biomedical.com

Peers

Peers Tab

6492.TWO

Senhwa Biosciences, Inc.

Cap

NT$3.2B

6885.TWO

BRIM Biotechnology, Inc.

Cap

NT$2.8B

6838.TWO

Formosa Pharmaceuticals, Inc.

Cap

NT$3.8B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6657.TW

What does Energenesis Biomedical CO.,LTD. do?: Energenesis Biomedical CO.,LTD. (6657.TW) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6657.TW's market cap?: Energenesis Biomedical CO.,LTD. (6657.TW) has a market capitalization of approximately $2.69 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6657.TW pay a dividend?: No — Energenesis Biomedical CO.,LTD. (6657.TW) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6657.TW profitable?: Energenesis Biomedical CO.,LTD. (6657.TW) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.